The Council of Scientific and Industrial Research (CSIR) is working on developing “mega labs” where large machines, called Next Generation Sequencing machines (NGS), which are also used for sequencing human genomes, will be repurposed to sequence 1,500-3,000 viral genomes at a go for detecting the SARS-CoV-2 novel coronavirus.
Daily Current Affairs Quiz 2020
Key-Points
The CSIR has partnered with the U.S.-based Illumina, a company that specialises in the manufacture of NGS machines. Five such sequencers, costing ₹4 crore each, are currently available in India.
These machines can substantially detect the presence of the virus even in several instances where the traditional RT-PCR (reverse transcription polymerase chain reaction) tests fail.
This is because the RT-PCR test identifies the SARS-CoV-2 virus by exploring only specific sections, whereas the genome method can read a bigger chunk of virus genome.
It can also trace the evolutionary history of the virus and track mutations more reliably. Unlike the RT-PCR that needs primers and probes the NGS only needs custom reagents.
